Please be aware that the information provided is a summary of select releases made to the ASX, as evaluated and interpreted by ASX Briefs. It is important to thoroughly read the entire original release before forming an opinion, rather than relying solely on the brief overview presented here. ASX Briefs is not associated with the ASX. ASX Briefs is an experimental AI project incorporating chatGPT, and as such, does not guarantee the accuracy of the information provided.
Opthea Limited announced the Phase 2b study results of OPT-302, a combination anti-VEGF-C/-D “trap” agent and Lucentis® (ranibizumab) for the treatment of wet age-related macular degeneration (AMD).
The prospective, randomized, controlled trial of 366 patients demonstrated that monthly intravitreal administration of 2.0 mg OPT-302 with ranibizumab standard of care, met the pre-specified primary efficacy endpoint of a statistically superior gain in visual acuity at 24 weeks.
Secondary outcomes were also positive for the combination therapy, which was published online in Ophthalmology, the journal of the American Academy of Ophthalmology.